Browsing: Life Settlements
Longevity and Mortality Investor’s coverage of the life settlement market. We are the leading source globally for life settlement analysis, commentary and insights.
Both micro and macro impacts for life settlement market but counterparty fundamentals remain strong.
For life settlement markets, earlier diagnosis of chronic diseases may reduce projected life expectancy, thereby influencing the expected duration of premium payments and the timing of policy maturities.
Two recent litigation cases produced opposite results for the life settlement market.
How durational mortality curves, stochastic A/E analysis and independent audits can strengthen investor confidence and fund sustainability.
LifeRoc Capital’s Brandon Marz provides his thoughts on the state of the life settlement industry’s secondary market in this month’s Q&A.
Delaware Supreme Court opinion says that the three-year statute of limitations applies to estates seeking to recover the death benefit from a STOLI policy.
Kosmos 2026-1 is the seventh asset-backed security issuance since 2019 for the firm and the third in six months.
One of the findings from the 2025 ELSA–Conning Life Settlement Investor Sentiment Study was that investors see life settlements sitting in their ‘resilience bucket,’ alongside private credit, infrastructure, and real assets.
New policies that will fuel future trades in the life settlement market continue to be issued in healthy volumes, but in real terms, are slowly contracting.
Griffith Ballard will continue to operate from Cedar Rapids under its existing leadership team.